News | September 21, 2009

IBA, Aposense to Co-Market New PET Agent

September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.

The new agent is a small molecule radiotracer which allows the imaging of apoptosis, a fundamental biological process of controlled cell death, from the early stages of the death process. Given the broad, cross disease role of apoptosis in a wide range of medical disorders, molecular imaging with [18F]-ML-10 is expected to play an important role in early detection of disease, monitoring of disease course, assessment of effect of treatment or development of novel therapies. In particular, [18F]-ML-10 may assist oncologists in evaluating tumor response to treatment much earlier than conventional imaging modalities such as CT or MRI. This may allow clinicians to identify earlier the most effective treatment within their therapeutic arsenal and provide personalized, safer and more cost-effective care. Among other clinical fields of potential applications of [18F]-ML-10 are cardiology and neurology.
[18F]-ML-10 illustrates the capability of nuclear molecular imaging to become a central discipline in healthcare and to deliver the clinical and economic benefits of Personalized Medicine.

The long-term, global agreement includes the collaboration and joint-funding by IBA and Aposense of phase III and subsequent clinical development of [18F]-ML-10. In addition, the companies will jointly market and sell [18F]-ML-10, with IBA primarily focusing on its core PET imaging and nuclear medicine market, and Aposense marketing to the referring clinical specialist market. Aposense will manufacture the proprietary ML-10 precursor and IBA will 18F-label and distribute the final drug product to clinical sites through its global network of PET radio-pharmacies. IBA and Aposense will share in revenue and development costs. Specific financial terms were not disclosed. Multi-center phase II clinical trials of [18F]-ML-10 are underway in a number of leading cancer centers in the United States, and are expected to be completed in 2010, to be followed by phase 3 trials during 2011/2012 for obtaining regulatory approvals.

This agreement expands the relationship established between IBA and Aposense in August 2008, when they entered into an agreement for 18F-labeling and distributing of ML-10 by IBA for Aposense’s multi-center clinical trials.

For more information: www.iba-worldwide.com and www.nst.co.il

Related Content

Researchers Trace Parkinson's Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init